Skip to main content
Global Public Company Research Platform

Institutional Equity Research for Undercovered Public Companies

Alliance Equity Research publishes independent and company-sponsored research on undercovered, emerging, and high-potential public companies globally.

Search AER-covered companies and Insights, or explore listed companies across global markets.

Analyst-built researchModel-driven analysisGlobal coverage

Latest Research

Recent initiation reports, research updates and company commentary from Alliance Equity Research.

Insights

Timely analysis of company developments, industry trends, capital markets activity, and emerging investment themes across global public markets.

Illustration of insulated pipes and blue pumps in an industrial mechanical room.Industrials & Aerospace

MasTec’s $1.25 Billion Murphy Deal Adds Maintenance Work That Outlasts Construction

MasTec agreed to pay approximately $1.25 billion in cash for Murphy, a mechanical contractor that installs and maintains systems in data centers, hospitals, factories and other facilities. Murphy’s projected $140 million of 2026 adjusted EBITDA implies an upfront price of about 8.9 times that figure, before a possible earnout. The acquisition adds skilled crews and gives MasTec a route to service work after construction ends. The price reflects earnings that have yet to be realized for the full year. The cash Murphy contributes after financing costs, equipment spending and working capital will help determine how quickly MasTec can reduce leverage.

Varun Bhauwala, MBANovember 20, 20266 min read
Read article
An empty shopping cart in a retail aisle stocked with holiday home goods.Market Commentary

More Shopping Trips Lift Target’s Earnings as Tariff Refunds Raise Its Outlook

Target’s third-quarter comparable sales rose 5.6%, driven mainly by more transactions. Gross margin improved even after removing $301 million of tariff refunds, although higher store labor and other costs absorbed some of the gain. The retailer raised its full-year earnings outlook, but most of the increase in the midpoint reflects refunds already recognized. The distinction matters as Target prepares to spend $5 billion to $6 billion on capital projects in 2027. Holiday traffic, markdowns and cash tied up in merchandise will help show how much of the improvement can carry forward.

Varun Bhauwala, MBANovember 18, 20266 min read
Read article
Unlabeled vaccine vial in a laboratory with an illustrative blood-cell background.Biotechnology & Healthcare

SELLAS Reports a Survival Benefit in AML as Its Cancer Vaccine Approaches FDA Review

SELLAS Life Sciences reported that its investigational cancer vaccine met the overall-survival endpoint in a Phase 3 trial of patients with acute myeloid leukemia who had reached a second or later remission and could not undergo a donor stem cell transplant. Median survival was 24.0 months with galinpepimut-S versus 14.7 months with investigator-selected care. The result provides a basis for a planned FDA discussion, while detailed control-arm, safety and secondary-endpoint data remain important to interpretation. SELLAS ended September with $134.7 million in cash after substantial warrant exercises.

Gaurav Premani, CFANovember 17, 20267 min read
Read article
Glass capsule on a laboratory surface against an abstract neural network.Biotechnology & Healthcare

Helus Pharma’s Depression Trial Succeeds as Safety and Funding Questions Move Forward

Helus Pharma’s HLP003 met the primary endpoint in its first pivotal depression trial, producing a 7.6-point advantage over placebo on a symptom scale at six weeks. Patients remained on their existing antidepressants, and the benefit persisted at the study’s 12-week assessment. The results strengthen the case for an intermittent add-on treatment, although the nature of three treatment-related serious adverse events remains undisclosed. Quarterly filings show $171.1 million in cash at September 30 and continued clinical spending ahead of a second pivotal readout expected in late 2027.

Gaurav Premani, CFANovember 16, 20268 min read
Read article
Conceptual image of an unbranded medicine vial and blood glucose meter.Biotechnology & Healthcare

Amylyx’s Detailed Avexitide Results Bring a Rare Post-Surgery Condition Closer to Treatment

Amylyx has released detailed Phase 3 results for avexitide, an experimental daily injection for recurrent low blood sugar after gastric bypass. In 78 adults receiving dietary management, the treatment reduced the rate of specified hypoglycemic events over 16 weeks versus placebo. The company plans to seek U.S. approval by year-end and prepare for a possible 2027 launch. The study provides a clearer picture of the potential benefit, while diagnosis, insurance access, the approved patient population and sustained treatment will determine the commercial opportunity.

Gaurav Premani, CFANovember 15, 20266 min read
Read article
Conceptual image of an unbranded nasal spray and a pulse oximeter on a clean surface.Biotechnology & Healthcare

Milestone Extends Its Cash Runway as CARDAMYST’s Early Sales Lag Launch Costs

Milestone Pharmaceuticals plans to cut operating expenses by approximately 30% as it develops a second potential use for CARDAMYST, its newly launched heart-rhythm nasal spray. Third-quarter product sales reached $963,000, while a separate $2 million licensing milestone accounted for most reported revenue. Management expects its cash to support operations into late 2028, around the time of a Phase 3 readout. Investors must weigh improving prescription activity and insurance coverage against launch spending, sales-based financing obligations and the time needed to establish a sustainable commercial business.

Gaurav Premani, CFANovember 14, 20267 min read
Read article
Conceptual aerial view of an open-pit mine with terraced earth and a winding haul road.Mining & Critical Minerals

Atalaya Adds Two Spanish Copper Projects as Its Growth Pipeline Competes for Capital

Atalaya Mining has acquired the former Tharsis and La Zarza mines in southern Spain for €125 million, adding large copper-bearing resources to a portfolio already led by its operating Riotinto complex and the proposed Touro development. The purchase follows a quarter of record EBITDA, helped by higher copper prices and increased sales. Although Atalaya paid €75 million upfront from cash, another €50 million is due within a year. The value of the expansion will depend on permitting, processing economics and how the new assets fit alongside existing investment priorities.

Nikhil Bhauwala, CFANovember 13, 20267 min read
Read article
Conceptual close-up illustration of red blood cells against a dark blue background.Biotechnology & Healthcare

Kura’s Leukemia Drug Sales Grow as Partnership and Financing Shape Future Returns

Kura Oncology’s first commercial medicine generated $13.9 million in third-quarter sales as more patients began treatment for a genetically defined form of acute myeloid leukemia. The launch is gaining traction, but Kura shares U.S. commercialization profits and losses with Kyowa Kirin and continues to fund extensive clinical development. A new Oberland Capital financing provides capital now and conditional access to more, alongside debt, equity issuance and a future sales-based obligation. The opportunity to treat newly diagnosed patients is larger than the current indication, but evidence from a Phase 3 program is not expected until 2028.

Gaurav Premani, CFANovember 12, 20268 min read
Read article

Explore Coverage

AER-covered companies combine public-company information with our proprietary research, updates, and commentary.

Find AER-Covered Companies

Explore AER-covered companies by sector, region, and market capitalization.

Our Research Approach

We study each company in the context of its industry and build financial models around how the business operates. Our reports show how changes in sales, costs, and investment affect cash flow and valuation.

  • Fundamental company analysis
  • Specialist industry expertise in healthcare and biotechnology, mining and critical minerals, and emerging technology
  • Financial modeling and scenario analysis
  • Ongoing coverage after initiation
  1. Operating Drivers

    Sales volumePricingOperating costs
  2. Financial Forecast

    Forecast table shown without numerical values
    MetricFY1FY2FY3FY4
    Revenue
    EBITDA
    Free cash flow
  3. Scenarios & Sensitivities

    Base caseUpsideDownside
  4. Valuation

    Discounted cash flow · Net asset value · Trading multiples

  5. Published Research

Public companies

Is Your Company Undercovered?

Alliance Equity Research works with listed companies, recently listed companies, and businesses preparing to list, with a focus on undercovered, emerging, and high-potential opportunities. Our coverage includes initiation research, detailed financial modeling, and ongoing research updates.

AER Coverage
  • Initiation Research
  • Financial Model
  • Ongoing Updates

Investor Discovery

  • AER Website
  • FactSet
  • LSEG Refinitiv
  • AlphaSense
  • Distribution Partners

Stay Current with AER

Choose the research and Insights updates you want to receive.

Email me:

Send me the AER email updates I select. I understand that I must confirm my subscription by email and can unsubscribe at any time. See our Privacy Policy.